TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07898306: A Two-part, Single Blind, Parallel Group, Phase 1 Study to Validate the Use of Fluorescence Activated Cell Sorting (FACS) Assay to Detect HEX17 Bound to Nasal Epithelial Cells (Part A) and to Investigate the Nasal Reside

Sponsor: Pneumagen Ltd, a subsidiary of NorthLinks Bio · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 44 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07898306 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07898306 Rescue Dossier →